Target Sequencing and Resequencing Market By Product Type (Instruments, Reagents and Consumables, Software and Services), By Technology (Next-Generation Sequencing, Sanger Sequencing, PCR-based Sequencing), By Application (Clinical Diagnostics, Drug Discovery and Development, Personalized Medicine, Research and Academia), By End-Use Industry (Healthcare and Clinical, Pharmaceutical and Biotechnology, Research and Academic Institutions, Contract Research Organizations), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Target Sequencing And Resequencing Market was valued at USD 8.3 Billion in 2024-e and will surpass USD 30.5 Billion by 2030; growing at a CAGR of 24.2% during 2025-2030.

The target sequencing and resequencing market has been growing rapidly due to the increasing demand for precise genetic testing and the expanding applications of genomic research. As technology evolves, the market continues to see new advancements in sequencing methods, which drive improvements in diagnostics, drug development, and personalized medicine. The growth of the healthcare sector and the push for more efficient, cost-effective ways to understand genetic information have fueled this market's expansion. With the rise of next-generation sequencing (NGS) technologies, the market offers significant opportunities for both established players and new entrants.

Instruments Segment is Largest Owing to Growing Demand for Sequencing Technologies

In the target sequencing and resequencing market, the instruments segment holds the largest share. This is driven by the increasing demand for high-performance sequencing platforms in both research and clinical settings. Sequencing instruments play a pivotal role in generating large amounts of genetic data, which is crucial for a wide range of applications, including diagnostics, drug development, and personalized medicine. The advancements in NGS instruments have particularly contributed to this segment's growth, as these systems are capable of handling high throughput, offering more accurate and faster sequencing.

As sequencing technology continues to evolve, there is a growing emphasis on improving instrument performance, reducing costs, and enhancing user experience. Companies like Illumina and Thermo Fisher Scientific are leading this segment with innovative instruments that meet the demands of the healthcare industry and research institutions. Additionally, the increasing trend of precision medicine, which requires high-quality sequencing data, continues to drive growth in the instruments segment.

NGS Technology is Fastest Growing Owing to its Broad Applications in Genomic Research

The fastest-growing segment in the target sequencing and resequencing market is next-generation sequencing (NGS) technology. NGS allows for the rapid sequencing of large amounts of DNA, making it highly suitable for a range of applications, from clinical diagnostics to personalized medicine. This technology’s ability to provide high-throughput, cost-effective solutions is driving its adoption across various end-user industries, including healthcare, pharmaceuticals, and biotechnology.

NGS technology has revolutionized the genomics field by enabling more efficient whole-genome sequencing, exome sequencing, and targeted gene sequencing. This growth is particularly evident in oncology, where NGS is used for genetic profiling of tumors to guide treatment decisions. Moreover, the rise of precision medicine and advancements in bioinformatics are expected to accelerate the adoption of NGS technology in the coming years.

Clinical Diagnostics Segment is Largest Owing to Increased Adoption in Healthcare

Among the applications of target sequencing, clinical diagnostics is the largest segment, fueled by the increasing demand for personalized medicine and genetic testing. As healthcare systems move toward more tailored treatments, genetic testing has become essential for the diagnosis of various diseases, including cancer, genetic disorders, and infectious diseases. Target sequencing technologies, which allow for the precise identification of disease-related genes, are becoming critical tools in clinical diagnostics.

The integration of genomic sequencing into routine clinical practices is expected to increase, especially with the rise of minimally invasive diagnostic tests. This growing focus on genomics in healthcare has positioned the clinical diagnostics segment as the leader in terms of market share within the target sequencing market. Companies focusing on clinical diagnostics are expanding their portfolio of sequencing solutions to cater to this increasing demand.

Healthcare and Clinical Segment is Largest Due to the Expanding Need for Precision Medicine

In terms of end-use industries, the healthcare and clinical segment dominates the target sequencing market. The growing emphasis on precision medicine and the need for accurate genetic data to guide therapeutic decisions have made healthcare the largest end-user industry for target sequencing. Genomic technologies are being widely adopted in hospitals, clinics, and research labs to provide more accurate diagnostics and tailored treatment plans for patients.

As more healthcare providers recognize the benefits of genomic sequencing, the integration of this technology into clinical settings is expected to increase. In particular, the expansion of genetic counseling services and the growing use of genomic data to predict disease risk are key drivers for this segment's growth. This focus on personalized care and the increasing number of patients seeking genetic testing will continue to make healthcare the largest end-use industry for target sequencing and resequencing technologies.

North America is the Largest Region Owing to High Healthcare Investments

Geographically, North America leads the target sequencing and resequencing market, owing to significant investments in healthcare and biotechnology sectors. The presence of leading healthcare providers, research institutions, and sequencing companies in the United States has positioned this region as the largest market for genomic technologies. Additionally, favorable reimbursement policies and the high adoption rate of precision medicine and genomic sequencing technologies are contributing factors to North America's dominance.

The U.S. government and private sector have heavily invested in the development of genomic technologies, and the demand for next-generation sequencing continues to rise in clinical diagnostics and research. Furthermore, the region's robust healthcare infrastructure and advanced biotechnology industry will ensure that North America remains a dominant force in the target sequencing market in the coming years.

Competitive Landscape and Leading Companies

The target sequencing and resequencing market is highly competitive, with a few dominant players and numerous emerging companies offering innovative solutions. Major companies in the market include Illumina, Thermo Fisher Scientific, Agilent Technologies, Roche, and Qiagen, all of which offer a wide range of sequencing instruments, reagents, and software. These companies invest heavily in R&D to enhance the efficiency and accuracy of their sequencing platforms, catering to the growing demand for personalized medicine and clinical diagnostics.

The competitive landscape is marked by strategic collaborations, mergers, and acquisitions as companies aim to expand their product portfolios and strengthen their position in the market. Additionally, with the growing focus on precision medicine, companies are focusing on developing sequencing technologies that offer higher throughput and lower costs. As the market continues to evolve, partnerships between genomics companies and healthcare providers will likely become more prominent to support the growing adoption of target sequencing solutions.

List of Leading Companies:

• Thermo Fisher Scientific
• Illumina Inc.
• Agilent Technologies
• Roche Diagnostics
• Qiagen N.V.
• PerkinElmer
• Oxford Nanopore Technologies
• BGI Genomics
• Bio-Rad Laboratories
• Pacific Biosciences
• New England Biolabs
• Primer Design Ltd.
• GATC Biotech
• DNASTAR, Inc.
• Asuragen, Inc.

Recent Developments:

• In 2024, Illumina announced a partnership with Merck to enhance genomic research tools for personalized cancer treatments.
• Thermo Fisher unveiled a state-of-the-art NGS platform aimed at improving genomic sequencing speed and accuracy in clinical research.
• Oxford Nanopore received FDA approval for its sequencing device to support genetic testing for clinical applications.
• Roche announced the expansion of its sequencing solutions to include new technologies targeting oncology diagnostics and therapeutic decision-making.
• Qiagen acquired a leading digital PCR technology company to enhance its precision medicine offerings, specifically for target sequencing applications.

Report Scope: